Comparative evaluation of cartridge-based nucleic acid amplification test, Ziehl-Neelsen smear microscopy, and culture in Lowenstein Jensen media for diagnosis of pulmonary and extrapulmonary tuberculosis in a tertiary care hospital in West Bengal, India
DOI:
https://doi.org/10.18203/2320-6012.ijrms20260628Keywords:
CBNAAT, Xpert MTB/RIF, Tuberculosis diagnosis, ZN smear microscopy, Lowenstein-Jensen culture, Rifampicin resistance, Molecular diagnosticsAbstract
Background: Tuberculosis remains a major global health problem and continues to rank among the leading causes of mortality worldwide. Early and accurate diagnosis is crucial for infection control and appropriate clinical management. Cartridge-based nucleic acid amplification test (CBNAAT) enables rapid and accurate molecular diagnosis of Mycobacterium tuberculosis, with simultaneous rifampicin resistance detection capability.
Methods: This cross-sectional study was conducted in Department of Microbiology in collaboration with Department of Chest Medicine, Medical College and Hospital, Kolkata, from February 2018 to January 2019. Two hundred specimens from suspected pulmonary and extrapulmonary tuberculosis cases were evaluated by CBNAAT, Ziehl-Neelsen (ZN) microscopy and culture in Lowenstein-Jensen (LJ) media. After excluding 14 erroneous specimens, the remaining 186 specimens were analysed using appropriate statistical methods.
Results: Of the 186 specimens included, CBNAAT was able to detect 27 positive cases (14.5%), while ZN microscopy and LJ culture identified 6.5% and 11.3% positive cases, respectively. Among the 27 CBNAAT-positive specimens, 20 were culture-positive, and 11 were found to be ZN smear positive – revealing statistically significant associations (p<0.001). Rifampicin resistance was found in 2 cases (7.4%). CBNAAT positivity showed significant association with haemoptysis (p=0.014) and longer duration of fever (p=0.006)
Conclusions: CBNAAT demonstrated superior diagnostic performance to ZN smear microscopy and LJ culture for rapid and accurate diagnosis of tuberculosis. Its ability to detect smear-negative cases highlights its value for early diagnosis and effective clinical management, particularly in high-burden settings such as India.
Metrics
References
Bai W, Ameyaw EK. Global, regional and national trends in tuberculosis incidence and main risk factors: a study using data from 2000 to 2021. BMC Public Health. 2024;24(1):12. DOI: https://doi.org/10.1186/s12889-023-17495-6
Trajman A. The social drivers of tuberculosis, reconfirmed. Lancet Infect Dis. 2024;24(1):5-6. DOI: https://doi.org/10.1016/S1473-3099(23)00390-0
Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in low- and middle-income countries: a systematic review. PLoS Med. 2006;3(12):e494. DOI: https://doi.org/10.1371/journal.pmed.0030494
Chakaya J, Petersen E, Nantanda R, Mungai BN, Migliori GB, Amanullah F, et al. The WHO Global Tuberculosis 2021 Report – not so good news and turning the tide back to End TB. Int J Infect Dis. 2022;124(1):S26-9. DOI: https://doi.org/10.1016/j.ijid.2022.03.011
CDC. Clinical overview of tuberculosis disease. Tuberculosis (TB). Available at: https://www. cdc.gov/tb/hcp/clinical-overview/tuberculosis-disease.html. Accessed on 25 November 2025.
Steingart KR, Ng V, Henry M, Hopewell PC, Ramsay A, Cunningham J, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(10):664-74. DOI: https://doi.org/10.1016/S1473-3099(06)70602-8
Acharya Tankeshwar. Löwenstein–Jensen (LJ) medium: preparation, uses. Microbe Online. 2016. Available from: https://microbeonline.com/prepara tion-uses-lowenstein-jensen-lj-medium. Accessed on 25 November 2025.
Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid Molecular Detection of Tuberculosis and Rifampin Resistance. N Engl J Med. 2010;363(11):1005-15. DOI: https://doi.org/10.1056/NEJMoa0907847
Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol. 2010;48(1):229-37. DOI: https://doi.org/10.1128/JCM.01463-09
Lee HS, Kee SJ, Shin JH, Kwon YS, Chun S, Lee JH, et al. Xpert MTB/RIF assay as a substitute for smear microscopy in an intermediate-burden setting. Am J Respir Crit Care Med. 2019;199(6):784-94. DOI: https://doi.org/10.1164/rccm.201804-0654OC
Ministry of Health and Family Welfare. India TB Report 2024. 2024. Available at: https://tbcindia. mohfw.gov.in/wp-content/uploads/2024/10/TB-Report_for-Web_08_10-2024-1.pdf. Accessed on 25 November 2025.
GBD 2021 Tuberculosis Collaborators. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Infect Dis. 2024; 24(7): 698-725. https://doi.org/10.1016/s1473-3099(24)00007-0 DOI: https://doi.org/10.1016/S1473-3099(24)00007-0
World Health Organization. Tuberculosis. World Health Organization. 2025. Available from: https:// www.who.int/news-room/fact-sheets/detail/ tuberculosis. Accessed 25.12.2025.
Ogbo FA, Ogeleka P, Okoro A, Olusanya BO, Olusanya J, Ifegwu IK, et al. Tuberculosis disease burden and attributable risk factors in Nigeria, 1990-2016. Trop Med Health. 2018;46:34. DOI: https://doi.org/10.1186/s41182-018-0114-9
Schaberg T, Reichert B, Schülin T, Lode H, Mauch H. Rapid drug susceptibility testing of Mycobacterium tuberculosis using conventional solid media. Eur Respir J. 1995;8(10):1688-93. DOI: https://doi.org/10.1183/09031936.95.08101688
Humayun M, Chirenda J, Ye W, Mukeredzi I, Mujuru HA, Yang Z. Effect of gender on clinical presentation of tuberculosis (TB) and age-specific risk of TB, and TB-human immunodeficiency virus coinfection. Open Forum Infect Dis. 2022;9(10):ofac512. DOI: https://doi.org/10.1093/ofid/ofac512
Shrivastava AK, Brahmachari S, Pathak P, Kumar R, Sainia T, Patel U, et al. Clinico-epidemiological profile of extra-pulmonary tuberculosis in central India. Int J Med Res Rev. 2015;3(2):223-30. DOI: https://doi.org/10.17511/ijmrr.2015.i2.046
Eddabra R, Neffa M. Epidemiological profile among pulmonary and extrapulmonary tuberculosis patients in Laayoune, Morocco. Pan Afr Med J. 2020;37:56. DOI: https://doi.org/10.11604/pamj.2020.37.56.21111
Sunnetcioglu A, Sunnetcioglu M, Binici I, Baran AI, Karahocagil MK, Saydan MR. Comparative analysis of pulmonary and extrapulmonary tuberculosis of 411 cases. Ann Clin Microbiol Antimicrob. 2015;14:34. DOI: https://doi.org/10.1186/s12941-015-0092-2
Gupta J, Joshi P, Gupta R, Gupta V. Comparative evaluation of GeneXpert with Ziehl-Neelsen (ZN) stain in samples of suspected tuberculosis cases at a tertiary care teaching hospital in central India. Cureus. 2024;16(10):e71402. DOI: https://doi.org/10.7759/cureus.71402
Babu CSR, Sumalatha N, Kumar AD, Ramesh KS. Comparative evaluation of sputum GeneXpert, smear microscopy, and culture in the diagnosis of pulmonary tuberculosis. J Chem Health Risks. 2025;15(6):341-7.
Yadav P, Mahour P, Agarwal A, Garg A. Comparative analysis of CBNAAT (GeneXpert) and Ziehl-Nielsen staining test as diagnostic modalities of tuberculosis. J Family Med Prim Care. 2024;13(1):124-8. DOI: https://doi.org/10.4103/jfmpc.jfmpc_277_23
Elbrolosy AM, El Helbawy RH, Mansour OM, Latif RA. Diagnostic utility of GeneXpert MTB/RIF assay versus conventional methods for diagnosis of pulmonary and extra-pulmonary tuberculosis. BMC Microbiol. 2021;21(1):144. DOI: https://doi.org/10.1186/s12866-021-02210-5
Martin-Higuera MC, Rivas G, Rolo M, Muñoz-Gallego I, Lopez-Roa P. Xpert MTB/RIF Ultra CT value provides a rapid measure of sputum bacillary burden and predicts smear status in patients with pulmonary tuberculosis. Sci Rep. 2023;13(1):1591. DOI: https://doi.org/10.1038/s41598-023-28869-6
Fradejas I, Ontañón B, Muñoz-Gallego I, Ramírez-Vela MJ, López-Roa P. The value of xpert MTB/RIF-generated CT values for predicting the smear status of patients with pulmonary tuberculosis. J Clin Tuberc Other Mycobact Dis. 2018;13:9-12. DOI: https://doi.org/10.1016/j.jctube.2018.04.002
Blakemore R, Nabeta P, Davidow AL, Vadwai V, Tahirli R, Munsamy V, et al. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. Am J Respir Crit Care Med. 2011;184(9):1076--84. DOI: https://doi.org/10.1164/rccm.201103-0536OC
Mol A, Sánchez-Montalvá A, Espinosa-Pereiro J, Aznar ML, Salvador F, Bosch-Nicolau P, et al. Usefulness of Xpert MTB/RIF and Xpert Ultra to categorize risk of tuberculosis transmission to household contacts. Open Forum Infect Dis. 2024;11(8):ofae450. DOI: https://doi.org/10.1093/ofid/ofae450
Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076. DOI: https://doi.org/10.1038/nrdp.2016.76
Flynn AG, Aiona K, Haas MK, Reves R, Belknap R. Clinical characteristics of active tuberculosis diagnosed after starting treatment for latent tuberculosis infection. Clin Infect Dis. 2020;71(5):1320-3. DOI: https://doi.org/10.1093/cid/ciz1157
Bailey SL, Grant P. 'The tubercular diabetic': the impact of diabetes mellitus on tuberculosis and its threat to global tuberculosis control. Clin Med (Lond). 2011;11(4):344-7. DOI: https://doi.org/10.7861/clinmedicine.11-4-344
Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9(12):737-46. DOI: https://doi.org/10.1016/S1473-3099(09)70282-8
Stevenson CR, Forouhi NG, Roglic G, Williams BG, Lauer JA, Dye C, et al. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health. 2007;7:234. DOI: https://doi.org/10.1186/1471-2458-7-234
Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5(7):e152. DOI: https://doi.org/10.1371/journal.pmed.0050152
Downloads
Published
How to Cite
Issue
Section
